NCT07489989
CT.gov ↗
CAR-T Cell Therapy + Chidamide and PD-1 Inhibitor Maintenance
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
pharma · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu
Daihong Liu trial registry — 1 ClinicalTrials.gov studies with program phase, status, and indication context.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 8
- Patents
- 0
Daihong Liu clinical trials
Registry index of 1 ClinicalTrials.gov studies linked to Daihong Liu programs — each row shows trial ID, program name, phase, status, and indication.
Daihong Liu trial registry — 1 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Daihong Liu.